Eine Studie zur Bewertung der Sicherheit und Wirksamkeit von Bomedemstat (MK-3543-017)
Eine multizentrische, offene Erweiterungsstudie zur Bewertung der Sicherheit und Wirksamkeit von Bomedemstat zur Behandlung von Teilnehmern, die an einer früheren klinischen Bomedemstat-Studie teilgenommen haben
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria:
- Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat;
- Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic response.
No hypothesis testing will be conducted in this study.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Toll Free Number
- Telefonnummer: 1-888-577-8839
- E-Mail: Trialsites@msd.com
Studienorte
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- Rekrutierung
- Royal Prince Alfred Hospital ( Site 1003)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61295155720
-
St Leonards, New South Wales, Australien, 2065
- Rekrutierung
- Royal North Shore Hospital ( Site 1001)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61299264383
-
-
Queensland
-
Buderim, Queensland, Australien, 4556
- Rekrutierung
- Sunshine Coast Hematology and Oncology Clinic ( Site 1006)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61754790000
-
Southport, Queensland, Australien, 4215
- Rekrutierung
- Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61756872712
-
-
South Australia
-
Adelaide, South Australia, Australien, 5000
- Rekrutierung
- Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61870740000
-
-
Victoria
-
Clayton, Victoria, Australien, 3168
- Rekrutierung
- Monash Health ( Site 1004)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61395956111
-
-
-
-
-
Hksar, Hongkong
- Aktiv, nicht rekrutierend
- Queen Mary Hospital ( Site 1601)
-
-
-
-
-
Alessandria, Italien, 15121
- Rekrutierung
- Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2703)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +39 0131 206440
-
Bologna, Italien, 40138
- Rekrutierung
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 2702)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390512143044
-
Varese, Italien, 21100
- Rekrutierung
- Ospedale di Circolo e Fondazione Macchi Varese ( Site 2701)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390332393906
-
-
Tuscany
-
Florence, Tuscany, Italien, 50134
- Rekrutierung
- Azienda Ospedaliera Universitaria Careggi ( Site 2700)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +39 0131 206440
-
-
-
-
-
Auckland, Neuseeland, 0622
- Aktiv, nicht rekrutierend
- North Shore Hospital-Department of Haematology ( Site 1401)
-
Auckland, Neuseeland, 2025
- Aktiv, nicht rekrutierend
- Aotearoa Clinical Trials ( Site 1400)
-
-
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Rekrutierung
- University of Michigan ( Site 6000)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 734-763-4695
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27705
- Rekrutierung
- DUHS Duke Blood Cancer Center ( Site 6005)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 919-668-1608
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Rekrutierung
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 888-577-8839
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- Rekrutierung
- UPMC Hillman Cancer Center ( Site 6004)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 412-864-6627
-
-
-
-
Hammersmith and Fulham
-
London, Hammersmith and Fulham, Vereinigtes Königreich, W12 0HS
- Rekrutierung
- Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +442083834340
-
-
Lincolnshire
-
Boston, Lincolnshire, Vereinigtes Königreich, PE21 9QS
- Rekrutierung
- Boston Pilgrim Hospital ( Site 3403)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 01205 446311
-
-
London, City of
-
London, London, City of, Vereinigtes Königreich, NW1 2PG
- Rekrutierung
- University College London Hospital ( Site 3400)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +442034472528
-
London, London, City of, Vereinigtes Königreich, SE1 9RT
- Rekrutierung
- Guy's & St Thomas' NHS Foundation Trust ( Site 3401)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +442071884259
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Is from a bomedemstat study sponsored by Imago BioSciences, Inc. (a subsidiary of Merck & Co., Inc.) or MSD, and established by the Sponsor as MK-3543-017 ready
- Has received at least 6 months of treatment with bomedemstat in the IMG-7289-202/MK-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator
- ET and PV participants from established feeder studies other than IMG-7289- 202/MK-3543-005 must have achieved confirmed hematologic response, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator
- Is not currently on a dose hold
- Participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat
Exclusion Criteria:
- Has received prohibited concomitant medications
- Ongoing or planned participation in another investigational study
- Has noncompliance in prior bomedemstat study receiving <90% of assigned doses excluding suspensions or holds as assigned by the investigator
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Bomedemstat
Participants will receive oral capsules of bomedemstat once daily for up to 10 years, with the starting dose as the same dose that the participant was on at the time of transition from the feeder study. |
10, 15, 20, and 50 mg oral capsules
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of participants with one or more adverse events (AEs)
Zeitfenster: Up to ~10 years
|
An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants with AEs will be presented. |
Up to ~10 years
|
|
Percentage of participants who discontinued study treatment due to an AE
Zeitfenster: Up to ~10 years
|
An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants who discontinued study treatment due to an AE will be presented. |
Up to ~10 years
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
For participants with ET: Duration of durable clinicohematologic response
Zeitfenster: Up to ~10 years
|
For participants who demonstrate durable clinicohematologic response (DCHR) in their feeder study, duration of durable clinicohematologic response (DODCHR) is defined as the time from the first documented evidence of confirmed reduction of platelet and white blood cell (WBC) counts until confirmed increase of platelet and WBC counts to above acceptable threshold, thrombotic or major hemorrhagic events, or disease progression to myelofibrosis (MF), myelodysplastic syndrome (MDS), or acute myeloid leukemia (AML). DODCHR will be reported. |
Up to ~10 years
|
|
For participants with ET or PV: Duration of clinicohematologic response
Zeitfenster: Up to ~10 years
|
For participants who showed clinicohematologic response in their feeder study, duration of clinicohematologic response is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC count until confirmed increase of platelet and WBC counts to above acceptable threshold, thrombotic or major hemorrhagic events or disease progression to MF, MDS, or AML, or phlebotomy (PV participants only). The duration of clinicohematologic response will be reported. |
Up to ~10 years
|
|
For participants with ET or PV: Duration of hematologic response
Zeitfenster: Up to ~10 years
|
For participants who showed confirmed hematologic response in their feeder study, duration of hematologic response is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC count until confirmed increase of platelet and WBC counts to above acceptable threshold, or phlebotomy (PV participants only). The duration of hematologic response will be reported. |
Up to ~10 years
|
|
For participants with ET or PV: Percentage of participants with transformation to MF or MDS/AML
Zeitfenster: Up to ~10 years
|
Disease Progression is defined as the transformation to post-ET myelofibrosis (ET participants only), post-PV myelofibrosis (PV participants only), spleen volume increase ≥25% (MF participants only), myelodysplastic syndrome, or acute myeloid leukemia as assessed by the investigator. The percentage of participants with transformation to MF or MDS/AML will be reported. |
Up to ~10 years
|
|
For participants with MF: Percentage of participants with worsening of splenomegaly or transformation to MDS/AML
Zeitfenster: Up to ~10 years
|
Spleen volume will be assessed by magnetic resonance imaging (MRI) (or computed tomography [CT] where applicable) at pre-specified timepoints. The percentage of participants with worsening of splenomegaly or transformation to MDS/AML will be reported. |
Up to ~10 years
|
|
For participants with MF, ET, or PV: Percentage of participants with thrombotic events
Zeitfenster: Up to ~10 years
|
Thrombotic events are defined as: new or recurrent acute myocardial infarction; unstable angina; stroke; transient ischemic attack (TIA); deep venous thrombosis (DVT); pulmonary embolism (PE); thrombotic digital ischemia; other thrombotic events such as peripheral limb ischemia or Budd-Chiari syndrome that are assessed to be due to underlying PV; other vascular occlusive events such as symptoms of cardiac, abdominal or peripheral limb ischemia supported by objective evidence of vessel disease and/or ischemia. The percentage of participants with thrombotic events will be presented. |
Up to ~10 years
|
|
For participants with MF, ET, or PV: Percentage of participants with major hemorrhagic events
Zeitfenster: Up to ~10 years
|
Hemorrhagic events are defined as: Major Bleeding (MB) Events such as fatal bleeding, and/or symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells; Clinically Relevant Non-Major Bleeding (CRNMB) Events Leading to hospitalization or increased level of care or clinically important, prompting a face-to-face medical evaluation. The percentage of participants with major hemorrhagic events will be presented. |
Up to ~10 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Medical Director, Merck Sharp and Dohme LLC
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach Standort
- Neubildungen
- Hämatologische Erkrankungen
- Blutgerinnungsstörungen
- Erkrankungen des Knochenmarks
- Hämorrhagische Störungen
- Erkrankungen der Blutplättchen
- Myeloproliferative Erkrankungen
- Knochenmarkneoplasmen
- Hämatologische Neubildungen
- Hämische und lymphatische Krankheiten
- Thrombozytose
- Thrombozythämie, essentiell
- Polycythaemia Vera
- Primäre Myelofibrose
- Bomedemstat
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 3543-017
- U1111-1294-8621 (Registrierungskennung: UTN)
- MK-3543-017 (Andere Kennung: MSD)
- 2023-506996-89-00 (Registrierungskennung: EU CT)
- 2023 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .